Orthofix's Q3 2024 net sales increased by 7% to $196.6 million. The company reported a net loss of $(27.4) million, with Non-GAAP adjusted EBITDA of $19.2 million. Free cash flow was $5.9 million. The company reiterated its full-year 2024 financial guidance and introduced new three-year financial targets.
Net sales increased by 7% year-over-year to $196.6 million.
U.S. Spine Fixation net sales grew by 18% compared to Q3 2023.
Bone Growth Therapies (BGT) net sales increased by 9%.
Company achieved free cash flow of $5.9 million in Q3 2024.
Orthofix reiterates its 2024 full-year guidance with net sales expected to range between $795 million to $800 million and non-GAAP adjusted EBITDA expected to range from $64 million to $69 million. The Company expects to continue to be free cash flow positive for the remainder of 2024.
Visualization of income flow from segment revenue to net income